Auxilium's Xiaflex in Peyronie's faces 3-month delay, but shares rise
This article was originally published in Scrip
Executive Summary
With Auxilium Pharmaceuticals' 28 August disclosure the US FDA had extended by three months its decision date for the supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum) as a treatment for Peyronie's disease – moving the Prescription Drug User Fee Act (PDUFA) action date from 6 September to 6 December – one might think the firm's stock would be adversely impacted.